Coreana Cosmetics Co., Ltd. Overview
Coreana Cosmetics is a mid-sized, vertically integrated Korean beauty manufacturer founded in 1988. It formulates and produces skincare, colour cosmetics, hair and body products at its own plant and laboratory in Cheonan. It sells them mainly through a door-to-door "beauty counsellor" direct-sales network, which it pioneered at scale in the early 1990s, and supplements this with specialty-store brands, an esthetic salon chain (Cellenique), online channels and exports. A wholly owned subsidiary in Tianjin, China, adds manufacturing and ODM/OEM capacity. Coreana was Korea's third-largest cosmetics company in the 1990s, with revenue above KRW 300 bn at its 2000–2001 peak. It is now a sub-KRW 100 bn niche player: FY2025 revenue was KRW 73.7 bn, with an operating loss of KRW 4.4 bn. The company is debt-light and asset-backed (P/B about 0.6x) but structurally challenged. Its strategic bets are the Ample:N derma brand, online direct sales and global K-beauty distribution.
What the company does. Coreana develops, manufactures and sells cosmetics: basic (skincare), colour, hair and body products. It also runs a skin-care salon chain and earns real-estate rental income. Morningstar classifies the business as household and personal products. Coreana's own product taxonomy groups the range into "solutions" lines: Power Cell, Collagen, Sun, Moisture, Homme, Wrinkle, White, Pore and Clean, plus make-up. The filed objects clause is far broader than current operations. It covers cosmetics and quasi-drug manufacturing, import/export, beauty academies, real-estate leasing, museum operation, health functional foods, e-commerce and skin-care devices. The company actively uses only a fraction of these.
Company's own description (paraphrased from filings and corporate profile). Management describes Coreana as a company that has pursued "Only the Best" quality for over three decades under the slogan "Art through Nature". Its stated management principles are customer satisfaction, ethical (정도) management and a "luxury-goods" (명품주의) product philosophy. Its own facilities handle research, production and distribution. The FY2025 business report ascribes the year's losses to three factors:
-
input-cost inflation that has become structurally embedded;
-
a prolonged slowdown in Greater China, together with weaker K-beauty competitiveness, which stalled exports;
-
a contracting person-to-person (방문판매) sales market.
Revenue model. Revenue is almost entirely product sales, with small service and rental components:
Product mix (latest). In Q2 2026, basic (skincare) cosmetics made up about 72% of revenue, "other cosmetics" (hair, body, other) about 22%, colour cosmetics about 5% and other sales about 1% (DART business segment data via Butler).
Value-chain position. Coreana is an integrated brand owner. It controls formulation (Song-pa Institute of Technology), manufacturing (Cheonan plants 1 and 2; Tianjin plant), brand marketing and a large part of distribution (direct sales, own salons, own online malls). This contrasts with asset-light "indie" K-beauty brands, which outsource production to ODMs such as Cosmax, Kolmar Korea or Cosmecca. Coreana also acts as an ODM/OEM supplier in China through its Tianjin subsidiary.
Customer types and end-markets. The core domestic customer is a middle-aged and older Korean woman, reached through relationship-based direct selling. That demographic is ageing, and its channel is shrinking. Ample:N, with K-pop brand ambassadors The Boyz's Hyunjae (2023–24) and Seventeen's Dokyeom (2025–26), targets 20–30-year-olds through Olive Young and Chicor. B2B customers include Chinese brand owners and distributors served from Tianjin, plus overseas distributors (Thailand Watsons, Philippines Shopee, Tmall Global flagship).
Independent characterisation. Coreana is a legacy direct-sales cosmetics house whose franchise has eroded for two decades. Revenue fell from roughly KRW 300–400 bn (2000–2003) to KRW 73.7 bn (FY2025). The company has kept its manufacturing and R&D base intact rather than becoming asset-light. That base, a debt-free balance sheet and a large treasury-share holding explain why the stock trades at about 0.6x book. The operating question is whether younger brands (Ample:N) and export or online channels can grow faster than the legacy direct-sales franchise declines. Through H1 2026, they have not.
Strategy
Stated strategy (themes from management communications).
2019 "Next 100 Years": team-innovation management, leading technology, customer-happiness management, with emphasis on R&D and global business.
30th anniversary (Nov 2018): "PASS 30 AHEAD 100", with brand-value innovation across R&D, marketing and production.
2023: "Serve the customer" (고객을 모시자), built on three principles: direct-sales innovation, stronger marketing, customer-centricity. The CEO also cited expansion of the bio business.
FY2025 disclosure (Feb 2026): management frames the challenge as structurally higher input costs, Greater China weakness and a shrinking person-to-person channel. No explicit turnaround programme with quantified targets was found.
Strategic initiatives, last 24 months (Oct 2024 – Oct 2026)
Medium-term targets and guidance. None published. Coreana does not issue earnings guidance, and no investor-day material was found. The last quantified public target found was 2012's KRW 120 bn revenue goal, which was not achieved.
ESG and sustainability commitments. CCM consumer-centred certification (8th renewal, 2022) and long-running International Vaccine Institute donations (13 consecutive years by Dec 2024). No emissions targets were published.
Products & Services
Coreana does not publish list prices or volumes in its filings, so pricing is "not publicly disclosed" unless stated. Launch years come from company history where available.
Core skincare brands (Basic cosmetics, ~72% of revenue)
| Brand | Description and positioning | Key lines / flagship products | Target customer | Launch / latest | Channel |
|---|---|---|---|---|---|
| LAVIDA (라비다) | Flagship premium anti-ageing brand of the direct-sales channel. Originally a functional brand of subsidiary Artpia. Sold in export markets as "Coreana Premium". | Power Cell Essence S (built on the in-house Signalosome™ ingredient, developed from miRNA research on wrinkles, whitening and moisture); Moisture Solution; Power Cell line; Sun Solution (packaging award). 12 consecutive "Brand of the Year" awards (2024); Moisture Solution and Power Cell shortlisted at Pentawards (Oct 2024). | Women 40+; direct-sales clientele | Relaunched 2012 (model Kim Ha-neul); ongoing | Direct sales, Lavida Shop online mall (Dec 2023), Lavida mall, exports |
| Ample:N (앰플엔) | Derma-cosmetic, "low-irritation, high-function" ampoule brand; the company's main growth and youth brand | Peptide Shot, Ceramide Shot and Hyaluronic Shot ampoules; Blemishot Ampoule (Mar 2025) and Blemishot Cream; Hypershot range (2026): Peptide, Ceramide and Cica PDRN ampoules; "Horangi Jakdo" and "Chaekgado" limited K-editions (traditional Korean painting packaging) | 20–30-year-olds; inbound tourists; overseas consumers | Launched 12 Apr 2017; Hypershot 2026 | Olive Young (online 2021; offline incl. Olive Young N Seongsu 2024), Chicor, Naver brand store, Watsons TH, Shopee PH, Amazon; pop-ups in Gangnam (May 2025) and Seongsu (2026), LA pop-ups planned |
| Orthia (오르시아 / Coreana Orthia) | Collagen anti-ageing line; ampoules became a China best-seller in 2015 (subsidiary Biocos sales expected +500%) | Perfect Collagen 24K Rose Gold Essence Toner Pad; 24K Rose Gold Essence White Tone-Up Cream SPF50+ PA++++; Perfect Collagen 28 Days Intensive Ampoule Cream; 28 Days Ampoule Sun Cream; Perfect Collagen Foaming Cleanser; 24K Rose Gold Magic | Mass-premium; China and SEA export | c. 2014–15 peak; ongoing | Export, cross-border e-commerce, Korean online |
| SENITE (세니떼) | Started as a fragrance and body brand; now also basic skincare. Main brand for the specialty-store (시판) channel and the name of the "Senite Beauty Shop" franchise network. | Senite Prestige skincare | Mass-premium | 2010 (model Seo Woo); ongoing | Senite Beauty Shops (200 contracted outlets by Nov 2013), specialty stores |
| PREANGE (프리엔제) | Originally a hypermarket brand; repositioned as a cosmeceutical brand | Cosmeceutical skincare | Ingredient-led consumers | Shinsegae Chicor online entry Jun 2021 | Chicor, online |
| RODIN (로댕) | Originally a men's specialty-store brand; now a functional cosmetics brand | Functional skincare | Men / functional | Ongoing | Specialty stores, online |
| GAON (가온) | Vegan cosmetics brand | Vegan skincare | Clean / vegan consumers | Ongoing | Online, retail |
| Korean Therapy Gayeonhwa (한방가연 / 가연화) | Herbal (hanbang) cosmetics | Herbal skincare | Older consumers; traditional-medicine positioning | Ongoing | Direct sales, specialty |
| Bichigain (비취가인) | Began in direct sales ("Powdery Spa"); now a specialty-store hanbang brand | Herbal skincare | Specialty-store customers | Ongoing | Specialty stores |
| ZAIN (자인) | Premium herbal brand; cited as popular in China (2015) | Premium herbal skincare | Premium / China | 2000s; ongoing | Direct sales, export |
| Fermented Mung Bean (발효녹두) | Natural-ingredient line descended from the "Mung Bean" franchise | Mung-bean based skincare | Natural-ingredient seekers | 2000s; ongoing | Various |
| Winage (위네이지) | Mainstream legacy line, first a sub-line of Astra21; widely known among older consumers | Premium Rose Vital line (Korea Package Design award 2023) | 40+ | 2000s; Rose Vital 2023 | Direct sales |
| INSLAB, ARTSCIEN, AGANOORI, SEDUIRE | Additional active brands listed in the S&P Global business description | Details not publicly disclosed | Various | — | — |
| Biocos (비오코스) | Brand/entity behind Orthia's China surge (2015) | Orthia ampoules | China | 2010s | Export |
| Coreana (corporate brand) | Masterbrand: legacy lines and new mass items | Coreana Aloe Soothing Gel (Jeju aloe, low-temperature extraction, with hyaluronic acid, centella and panthenol; launch dated c. 2025 from press archive); Coreana Black Diamond; Coreana Bio (trademarks) | Broad | Aloe gel c. 2025 | Coreanamall, online |
Colour cosmetics (~5% of revenue)
| Brand | Description | Notes |
|---|---|---|
| Ten Seconds (텐세컨즈) | Coreana's make-up line | Specific SKUs not publicly disclosed |
| Merbe (메르베), legacy | 1994 specialty-store brand that succeeded Artpia | Produced the hit "Merbe Face Powder"; status not confirmed |
Hair, body and other cosmetics (~22% of revenue)
These categories include shampoo, rinse and body products, a heritage dating to the company's first own product, the 1989 Bubble Bubble shampoo. Senite originally carried fragrance and body ranges. The company also manufactured toothpaste and mouthwash (2016 statement on CMIT/MIT). Line-by-line catalogue data for hair and body SKUs is not publicly disclosed.
Services, devices and non-cosmetic offerings
| Offering | Description | Status |
|---|---|---|
| Cellenique (세레니끄) | Premium esthetic skin-care salon chain using and retailing its own product line. 15 branches as of May 2026: Gongdeok, Dangsan, Daechi, Mokdong, Banpo Xi, Bangbae-Sadang, Yeouido, Hannam-Oksu, Wangsimni, Eunpyeong, Jamsil, Gwacheon, Sanbon, Wirye, Pyeongchon. Two closed in 2025: Yongsan-Namyeong and Jamsil World Mark. | Operating; awards include the "First Brand" esthetic category, 9 consecutive years (Jan 2025) |
| Everview Pro | Premium home-care beauty device with seven functions, unveiled under Ample:N (2026) | New; pricing not disclosed |
| Wellbeing Life (웰빙라이프) | Health functional food brand | Small; status not disclosed |
| Coreana Beauty Centre / Beauty Institute | Beauty education and counselling centres | Lifelong-education institute since closed |
| Real-estate rental | Leasing of owned property | Ongoing |
Discontinued or heritage brands (context for brand equity)
Ensia (orange line, a major hit), Astra21 (sports cosmetics under a Samsung C&T licence, modelled by Jung Woo-sung in 2000), Artpia (1990–95 specialty-store brand), Crezh (1995, withdrawn after a trademark dispute with Courrèges), Bio Defense (its replacement), Ceredie, Cerebio. The legacy "Mud Pack" was a Chosun Ilbo hit product in 1993 and 1998. Yves Rocher, distributed 1989 onward (ADN, Florilia, Sérélis, Trimaran), was the founding licence.
Financial Narrative
Income statement (consolidated)
Notes on sources and precision
-
Revenue, operating income and net income come from DART via Butler/Chickstock.
-
FY2025 exact figures from the 10 Feb 2026 30%-change disclosure: revenue KRW 73,677,182,497; net loss KRW 7,746,558,039. Operating loss was KRW 4.394 bn (Namu Wiki/DigitalToday).
-
FY2024 exact: revenue KRW 82,451,674,673; net income KRW 783,926,037. FY2024 operating income back-solves to about KRW 0.44 bn from the reported −1,096.8% change.
-
FY2022 net income appears as KRW 1.5 bn (Butler) and KRW 1.6 bn (Dealsite, citing the Feb 2023 disclosure), a minor rounding or attribution discrepancy.
-
FY2025 EBITDA of about KRW −1.5 bn is TradingView's computed figure (EBITDA margin −2.55%). Its period basis is not stated, so treat it as approximate. It implies D&A of roughly KRW 2.5–3.0 bn a year.
-
Gross profit: Simply Wall St (S&P Global data) shows TTM to Sep 2025 revenue KRW 76.5 bn and gross profit KRW 27.1 bn (35.4% margin). TTM to Jun 2026 shows KRW 71.7 bn and KRW 24.2 bn (33.7%).
-
TTM EPS is −KRW 225 (Chickstock, H1 2026 TTM) versus −KRW 278.45 (Simply Wall St, TTM Jun 2026). The gap likely reflects differences in the share base (treasury shares) and minority-interest treatment.
-
Dividends: no dividend yield is shown for the current period (Butler: "–").
Revenue CAGR. FY2021–FY2025: −4.1% a year (KRW 87.1 bn to 73.7 bn). FY2016 to FY2025, using KRW 117.7 bn for FY2016 as reported on the Incruit company profile: about −5.1% a year.
Parent-company (separate) results
Sources: Incruit/NICE; Namu Wiki (FY2025 separate operating loss KRW 4.63 bn, net loss KRW 6.75 bn).
Balance sheet
Sources and notes
-
FY2025 consolidated total assets KRW 108.35 bn and liabilities KRW 22.26 bn are from Namu Wiki's reproduction of the FY2025 business report; equity is derived.
-
End-2024 current assets and current liabilities are from iNews24 (Jul 2025), citing DART.
Debt profile (known data points)
-
Short-term borrowings were KRW 4.75 bn at 31 Mar 2025, maturing Mar 2026. Management stated no other loans. Debt ratio was 24.32% and net debt ratio 0.72% at that date (iNews24).
-
The July 2025 treasury-share sale (KRW 5.57 bn) was explicitly to repay this loan and fund operations.
-
By Jun 2026, Simply Wall St shows debt/equity of 1.2%. On roughly KRW 84 bn of equity, that implies borrowings of about KRW 1 bn, so net debt is effectively nil or negative.
-
Total equity at Jun 2026 is about KRW 84 bn, consistent with BPS of KRW 2,103 and P/B of 0.59x at a KRW 49.8 bn market cap.
Cash flow
Sources and notes
-
FY2025 operating cash flow of −KRW 1.6 bn is from Chickstock's financial-intelligence flag (operating loss plus negative operating cash flow).
-
The FY2024 buyback value is the board-approved amount: an acquisition decision of about KRW 0.8 bn, announced roughly December 2024 (Edaily).
-
Earlier buyback decisions: KRW 2.84 bn (440,000 shares, Jun–Jul 2017); KRW 0.29 bn (100,000 shares, Jun 2022); trust contract of KRW 3 bn extended to Jun 2014.
-
The FY2025 disposal was 2,000,000 shares at KRW 2,784 (25 Jul 2025).
Ratios
Notes
-
FY2025 ROE, ROA and asset turnover are computed on year-end balances; average balances were not available.
-
TTM ROE to Jun 2026 is −10.7% (Chickstock) or −11.3% (Chickstock financials page, different cut-off).
-
Interest coverage is negative in FY2025 (operating loss).
-
Debt/equity is 1.2% at Jun 2026 (Simply Wall St).
Commentary — trends, inflections and drivers
Revenue: structural decline with China volatility layered on top. Coreana's revenue has been on a long downward path since its 2000–2003 peak, when annual sales approached KRW 300–400 bn. Press accounts attribute the decline to the 2003 credit-card crisis, the rise of single-brand road shops (Missha, The Face Shop and similar) and new direct-sales entrants that undercut the company's core channel. Within FY2021–FY2025, the pattern alternates:
-
FY2022 contraction (−7.7%), driven by China's Covid lockdowns hitting the offline-heavy Tianjin subsidiary;
-
FY2023 recovery (+7.0%), with Q1 2023 described as export-driven;
-
renewed declines in FY2024 (−4.1%) and FY2025 (−10.6%).
The FY2025 decline was sharpest in the implied subsidiary contribution, down about 43%, while the parent fell a more modest 2.9%.
Profitability: margins have compressed to below break-even. Operating margin fell from 3.9% (FY2021) to around 1% (FY2022–FY2023), 0.5% (FY2024) and −6.0% (FY2025). Management's FY2025 explanation names a structural rise in raw-material and packaging costs and the loss of operating leverage on a shrinking top line. Gross margin of about 34–35% (TTM) is low for an own-brand cosmetics company; Korean beauty brand owners typically operate well above 50%. The H1 2026 operating loss of about KRW 1.6 bn is a large improvement on FY2025's run-rate. However, Q2 2026 (−KRW 1.1 bn) deteriorated from Q1 2026 (−KRW 0.5 bn).
Below-the-line items. FY2025 net loss (−KRW 7.7 bn) exceeded operating loss (−KRW 4.4 bn) by about KRW 3.3 bn. That points to non-operating charges: impairments, valuation losses on financial or equity-method assets, or tax effects. Q1 2026's small net profit (KRW 0.2 bn) despite an operating loss suggests non-operating income (interest, rental, FX) in that quarter.
Balance sheet: conservative and asset-heavy. With about KRW 108 bn of assets, only about KRW 22 bn of liabilities, minimal borrowings and owned real estate (Cheonan HQ/plant, Gwanggyo building), Coreana's solvency risk is low. The company has twice used asset monetisation to stay debt-free: the Seocho building sale (KRW 32 bn, 2011–12) and the 2025 treasury-share sale. The main financial risk is not leverage but cash burn. Negative operating cash flow (FY2025) combined with continued losses will gradually erode equity and liquidity if the business does not return to break-even.
Capital allocation. For over a decade Coreana bought back stock periodically (2013 trust, 2017, 2022, 2024), accumulating about a quarter of its issued shares in treasury. The July 2025 reversal, which sold 5% of the company for a modest short-term loan, was criticised as unnecessary given end-2024 current assets of KRW 26.2 bn against current liabilities of KRW 13.6 bn. It signals that management is prioritising liquidity over per-share value. No dividends appear to have been paid recently.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Ownership | Function | Source |
|---|---|---|---|---|
Coreana Cosmetics Co., Ltd. | Parent (listed) | — | Brand ownership, Cheonan manufacturing, R&D, domestic sales, exports | DART |
Coreana Tianjin Co., Ltd. (코리아나천진유한공사) | Consolidated subsidiary | 100% | China manufacturing, local sales, ODM/OEM | Company; Namu Wiki; Dealsite (2023) |
Artpia Co., Ltd. (㈜아트피아) | Consolidated subsidiary | 63.21% | Cosmetics brand and sales entity (est. 1997) | Company; Namu Wiki |
Coreana Bio Co., Ltd. (코리아나바이오) | Associate (equity method) | 20.20% | Bio/ingredient affiliate; also holds 300,000 Coreana shares (0.75%) as a related party | Company; large-shareholding report (Sep 2026) |
Segment Revenue
| Category | Contents | Share of revenue, Q2 2026 (%) |
|---|---|---|
Basic (skincare) cosmetics | Toners, emulsions, essences, ampoules, creams, sun care, cleansers | 72 |
Other cosmetics | Hair care, body care, fragrance, other | 22 |
Colour cosmetics | Make-up (e.g., Ten Seconds, cushions, powders) | 5 |
Other sales | Services, rental, merchandise | 1 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated revenue (KRW Bn) | 86.0 | 82.5 | 73.7 |
Parent (separate) revenue (KRW Bn) | 70.4 | 66.6 | 64.7 |
Implied subsidiaries net of eliminations (KRW Bn) | 15.6 | 15.9 | 9.0 |
Parent share of consolidated revenue (%) | 81.9 | 80.7 | 87.8 |
Parent revenue YoY growth (%) | — | -5.4 | -2.9 |
Implied subsidiaries YoY growth (%) | — | 1.9 | -43.4 |
Revenue by Segment
| Metric | FY2023 | FY2024 |
|---|---|---|
Likely Tianjin subsidiary revenue (KRW Bn) | 18.2 | 16.3 |
Likely Tianjin subsidiary operating profit (KRW Bn) | 0.75 | 1.75 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 87.1 | 80.4 | 86.0 | 82.5 | 73.7 |
Revenue growth YoY (%) | — | -7.7 | 7.0 | -4.1 | -10.6 |
Operating income (KRW Bn) | 3.4 | 0.9 | 0.9 | 0.4 | -4.4 |
EBITDA (KRW Bn) | — | — | — | — | -1.5 |
Net income (KRW Bn) | 3.3 | 1.5 | 1.8 | 0.8 | -7.7 |
Operating margin (%) | 3.9 | 1.1 | 1.0 | 0.5 | -6.0 |
Net margin (%) | 3.8 | 1.9 | 2.1 | 1.0 | -10.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Separate revenue (KRW Bn) | 70.4 | 66.6 | 64.7 |
Separate operating income (KRW Bn) | — | — | -4.6 |
Separate net income (KRW Bn) | 1.8 | 0.1 | -6.8 |
Separate total equity (KRW Bn) | 86.2 | 86.1 | 83.7 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 19.1 | 20.5 | 16.8 | 17.4 | 18.6 | 18.9 |
Revenue YoY (%) | — | — | -14.0 | — | -2.4 | -7.7 |
Operating income (KRW Bn) | — | — | — | — | -0.5 | -1.1 |
Net income (KRW Bn) | — | — | -2.6 | — | 0.2 | -1.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (KRW Bn) | — | 108.3 |
Total liabilities (KRW Bn) | — | 22.3 |
Total equity (KRW Bn) | — | 86.1 |
Current assets (KRW Bn) | 26.2 | — |
Current liabilities (KRW Bn) | 13.6 | — |
Liabilities-to-equity (%) | — | 25.9 |
Separate total assets (KRW Bn) | — | 97.8 |
Separate total liabilities (KRW Bn) | — | 14.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2024 | FY2025 |
|---|---|---|
Operating cash flow (KRW Bn) | — | -1.6 |
Treasury-share purchases (KRW Bn) | 0.8 | — |
Treasury-share disposal proceeds (KRW Bn) | — | 5.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%) | — | -9.0 |
ROA (%) | — | -7.1 |
Current ratio (x) | 1.93 | — |
Liabilities / equity (%) | — | 25.9 |
Asset turnover (x) | — | 0.68 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea-domiciled revenue, parent separate (KRW Bn) | 70.4 | 66.6 | 64.7 |
China-domiciled revenue proxy, consolidated minus separate (KRW Bn) | 15.6 | 15.9 | 9.0 |
Korea-domiciled growth (%) | — | -5.4 | -2.9 |
China proxy growth (%) | — | 1.9 | -43.4 |
China proxy share of consolidated revenue (%) | 18.1 | 19.3 | 12.2 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last close | KRW 1,240 (+2.06%) | 19 Oct 2026, Chickstock (KOSCOM) |
Market capitalisation | KRW 49.8 bn | 19 Oct 2026 |
52-week high / low | KRW 3,055 (30 Oct 2025) / KRW 1,150 (30 Jul 2026) | Chickstock |
Price on 10 Feb 2026 (FY2025 results) | KRW 2,260 | DigitalToday |
Treasury-share disposal price | KRW 2,784 | 25 Jul 2025 |
Daily trading value | ~KRW 16.2 m (19 Oct 2026); illiquid | Chickstock |
Beta (1Y) | 0.19 | TradingView |
1-year price change | About −52% (TradingView snapshot); about −59% from the 52-week high to the current price | TradingView; Chickstock |
Share Price
| Metric | Jul 2025 | Feb 2026 | Sep 2026 | Oct 2026 |
|---|---|---|---|---|
Share price (KRW) | 2,784 | 2,260 | 1,327 | 1,240 |
Valuation Multiples
| Multiple | Coreana | Korean cosmetics sector median | Basis |
|---|---|---|---|
P/E (TTM) | Negative (−5.53x) | 12.71x (35 profitable names, 8 Oct 2026) | Chickstock, H1 2026 TTM |
P/B | 0.59x | 1.25x to 1.29x (55–57 names) | Chickstock |
P/S (EV/Sales proxy) | 0.69x | 0.99x to 1.11x | Chickstock |
EV/EBITDA | Not meaningful (negative EBITDA) | — | TradingView EBITDA ~−KRW 1.5 bn |
Profitability-matched peers (10 companies) | — | Typically ~13.0x P/E | Chickstock |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy | No published policy; no current dividend yield (Butler, Oct 2026). |
Buyback history | Trust contract of KRW 3 bn extended to Jun 2014; 440,000 shares (KRW 2.84 bn) decided Jun 2017; 100,000 shares (KRW 0.29 bn) decided Jun 2022; KRW 0.8 bn decided c. Dec 2024 |
Treasury disposals | 2,000,000 shares (KRW 5.57 bn), 25 Jul 2025, the first in company history |
Current treasury holding | 19.50% (~7.8 m shares) |
Current buyback authorisation | None active found |
Moody's / S&P / Fitch | Not rated |
Domestic corporate credit evaluation | Rated "양호" (sound) as of Mar 2026 on the Catch/NICE profile; this is a commercial credit evaluation, not a bond rating |
Bonds outstanding | None identified |
Debt maturity profile | Short-term borrowings of KRW 4.75 bn were due Mar 2026, with repayment funded by the Jul 2025 treasury sale. Debt/equity was 1.2% at Jun 2026, so no material maturities are outstanding. |
Analyst Conclusions
Management guidance. None issued. Management's only forward-looking framing in filings is diagnostic: cost inflation, China and the decline of the person-to-person channel are structural. Brand-level communications point to global expansion of Ample:N, including overseas pop-ups.
Consensus growth expectations. None; the stock is uncovered. Using the run-rate method, H1 2026 revenue of KRW 37.5 bn annualises to about KRW 75 bn, roughly flat to slightly up on FY2025's KRW 73.7 bn. The H1 operating loss of about KRW 1.6 bn annualises to about −KRW 3 bn, an improvement on −KRW 4.4 bn but still a loss. This is an analytical extrapolation, not a forecast from any third party.
Bull case
-
Deep asset discount with a capital-return lever. At 0.59x book, the market prices Coreana well below net assets, which include owned plants, a Gwanggyo building and an R&D campus. A 19.5% treasury holding could be cancelled to raise BPS. Korea's value-up policy push and the ownership-reporting transition to Yu Hak-soo (Sep 2026) create a plausible catalyst window.
-
Loss narrowing is visible. The operating loss improved from −KRW 4.4 bn (FY2025) to about −KRW 1.6 bn (H1 2026), and Q1 2026 posted a net profit. Further cost actions (salon rationalisation, Tianjin cost control, which raised FY2024 subsidiary operating profit by KRW 1.0 bn) could restore break-even on flat revenue.
-
Ample:N rides the strongest K-beauty vector. Skincare exports are growing 25% and US exports 41.5% (H1 2026). Ample:N already has Olive Young flagship placement, K-pop ambassadors, barrier, peptide and PDRN products and a device extension. Modest export traction would be material on a KRW 74 bn revenue base.
Bear case
-
Structural decline outruns new initiatives. Revenue fell in three of the last four years. H1 2026 continued to decline (Q2 −7.7%) despite record national exports, which shows Coreana is losing share. The person-to-person channel driving Lavida is contracting by management's own admission.
-
China leg is breaking. The implied subsidiary contribution fell 43% in FY2025. The KAIXIN contract term ends in 2026, and national exports to China are falling. Further Tianjin erosion would remove the group's historically profitable subsidiary.
-
Capital allocation and governance weigh on value realisation. The 2025 treasury-share sale for a small loan, the low family economic ownership (16.08%) and the absence of dividends, guidance or IR engagement suggest the asset discount may persist. Continued negative operating cash flow could force further asset monetisation on poor terms.
Key catalysts and monitorables (next 12 months)
| Catalyst | Timing | What to watch |
|---|---|---|
| Q3 2026 quarterly report | By 16 Nov 2026 | Whether the Q2 operating loss (−KRW 1.1 bn) reverses; China proxy trend |
| FY2026 results / 30%-change disclosure | ~Feb 2027 | Return to operating break-even vs a second loss year |
| KAIXIN contract renewal or replacement | 2026–27 | Disclosure of new China ODM contracts |
| Treasury-share decision (cancellation or further disposal) | Any time; AGM Mar 2027 | Direction of capital allocation |
| Ample:N overseas pop-ups (LA) and US e-commerce | 2026–27 | Disclosed export growth |
| Ownership and succession filings | Ongoing | Further transfers between Yu Sang-ok and Yu Hak-soo; any change in control |
| Gross margin | Quarterly | Recovery above ~35% needed for sustainable profitability |
| Operating cash flow | Semi-annual | Sign change to positive |
Concluding analyst verdict
Coreana Cosmetics is a heritage Korean beauty franchise in managed decline. It has a fortress-like balance sheet and has so far been unable to participate in the most powerful growth cycle in its industry's history. While Korean cosmetics exports rose 27% to a record USD 7.0 bn in H1 2026, Coreana's consolidated revenue fell year on year in both quarters. Its FY2025 result was a KRW 4.4 bn operating loss on KRW 73.7 bn of revenue. The causes are structural rather than cyclical: the company's core person-to-person sales channel is shrinking, its China subsidiary's contribution nearly halved, and a gross margin of about 34% leaves little room to absorb input-cost inflation.
The bull case is primarily an asset story. At KRW 1,240 the stock trades at 0.59x book and about 0.7x sales. It has negligible debt, owned industrial and office real estate, and a 19.5% treasury block that could be cancelled. Losses narrowed meaningfully in H1 2026, and Ample:N is positioned in the right product trends and retail doors. If management combined cost discipline with treasury-share cancellation or an asset unlock, the discount to book could narrow.
The evidence on capital allocation, however, points the other way. The first-ever treasury-share sale in July 2025 was used to retire a small loan. There is no dividend, guidance or investor engagement, and controlling-family economic ownership is low at 16.08%. Until Coreana demonstrates either operating break-even, positive operating cash flow or a shareholder-aligned use of its treasury stake, the valuation discount is more likely to persist than close.
The overall assessment is a deep-value, low-quality situation with asymmetric dependence on management action. Investors should treat the Q3 2026 report, any KAIXIN successor contract and any treasury-share resolution as the decisive near-term signals. Absent these, the risk of slow book-value erosion through continued losses outweighs the optionality.
APPENDIX — SOURCE KEY
Primary filings (DART/KIND) are referenced through the reproductions listed below; figures were cross-checked where two or more sources were available.
-
DigitalToday — FY2025 30%+ P&L change disclosure (10 Feb 2026): https://www.digitaltoday.co.kr/news/articleView.html?idxno=629677
-
DigitalToday — Large-shareholding report, 15 Sep 2026: https://www.digitaltoday.co.kr/disclosure/articleView.html?idxno=700789
-
Datatooza — Group holdings 16.08% (15 Sep 2026): https://www.datatooza.com/article/20260915162613208552ef328a07_80
-
Butler (DART-derived financials, segment mix, treasury ratio): https://www.butler.works/ko/companies/00152589
-
Chickstock — Price, valuation, Q1/Q2 2026 results: https://www.chickstockfi.com/stocks/027050
-
Chickstock — Financials and sector medians: https://www.chickstockfi.com/stocks/027050/financials
-
Chickstock — Earnings calendar: https://www.chickstockfi.com/stocks/027050/earnings
-
Simply Wall St (S&P Global data) — TTM revenue, gross profit, debt/equity, Q3 2025: https://simplywall.st/stock/kosdaq/a027050
-
TradingView — EBITDA, beta, employees: https://kr.tradingview.com/symbols/KRX-027050/
-
Morningstar — Business description, employees: https://morningstar.com.au/investments/security/XKRX/027050
-
FinancialReports.eu — 2025 proxy solicitation document: https://financialreports.eu/filings/7970015/content
-
Namu Wiki — Company history, subsidiaries, brands, Cellenique, FY2025 balance sheet: https://namu.wiki/w/%EC%BD%94%EB%A6%AC%EC%95%84%EB%82%98%ED%99%94%EC%9E%A5%ED%92%88
-
Incruit — Separate financials 2023–2025, objects clause, history: https://www.incruit.com/company/10713545/ ; https://www.incruit.com/company/1691155696
-
Catch/NICE — Employees, separate vs consolidated revenue, credit evaluation: https://www.catch.co.kr/Comp/CompSummary/026468
-
iNews24 — July 2025 treasury-share disposal: https://www.inews24.com/view/1869437
-
Dealsite — FY2022 results and Tianjin (Feb 2023): https://dealsite.co.kr/articles/98553
-
Dealsite — CEO share purchases and China ODM strategy (Dec 2021): https://dealsite.co.kr/articles/81410
-
Bizwatch — Governance and ownership (Jan 2022): https://news.bizwatch.co.kr/article/governance/2022/01/01/0001
-
TaxWatch — 2015 gift and gift-tax sales (Mar 2020): https://www.taxwatch.co.kr/article/tax/2020/03/11/0003
-
Etoday — Sibling ownership changes (2019): https://www.etoday.co.kr/news/view/1816652
-
Etoday — Orthia China boom and Tianjin plant (2015): https://www.etoday.co.kr/news/view/1110340
-
Saturday Economy — 2012 zero-borrowing declaration and Seocho sale: https://sateconomy.co.kr/news/view/179587815920884
-
Edaily — Historical results (FY2012, FY2014, Q2 2015, Q1 2016) and buyback decisions
-
Cosinkorea — Ample:N Seongsu pop-up: https://www.cosinkorea.com/news/article.html?no=57016
-
Cosinkorea — Aloe Soothing Gel: https://www.cosinkorea.com/news/article.html?no=55475
-
Cosinkorea — Kolmar Korea Q2 2026: https://www.cosinkorea.com/news/article.html?no=58067
-
Ilgan Sports — Korean cosmetics exports H1 2026: https://isplus.com/article/view/isp202607020143
-
Tax Times — 2025 cosmetics exports USD 11.4 bn: https://taxtimes.co.kr/news/article.html?no=275558
-
CNC News — Cosmax and Kolmar Korea FY2024: https://www.cncnews.co.kr/mobile/article.html?no=9876
-
CNC News — 2019 management agenda: https://www.cncnews.co.kr/mobile/article.html?no=4454
-
Kukinews — Cosmecca Korea Q3 2025: https://www.kukinews.com/article/view/kuk202511060201
-
Segye Ilbo — 30th anniversary (2018): https://www.segye.com/newsView/20181116000458
-
Sports Kyunghyang — 2016 CMIT/MIT statement: https://sports.khan.co.kr/article/201609281136003/amp
-
Lazada Brand Wiki — Corporate profile (481 IP assets, CCM): https://brandwiki.lazada.com.ph/coreana/
-
IPqwery — Trademark filings: https://ipqwery.com/ipowner/en/owner/ip/303084-coreana-cosmetics-co-ltd.html
-
Seoul Shinmun (1993, 2004), Money Today (2007), Kyunghyang (2000), Hankyung Magazine, Bravo Etoday (2020) — founder profiles
Data gaps to close from DART before use in a board document: FY2021–FY2025 gross profit, EBITDA, EPS and DPS; cash, debt and capex series; R&D expense; auditor; ISIN; board composition and pay; FY2025 non-operating items; KAIXIN contract status; the reason for the Aug–Sep 2026 change in shareholding reporter.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background / education | Age |
|---|---|---|---|---|
Yu Sang-ok (유상옥) | Founder; Chairman, listed as Representative Director & Chairman in public profiles. Current registered-director status should be confirmed in the latest DART report. | Founder 1988; CEO 1988–2008 | Joined Dong-A Pharmaceutical in 1959 in its first open-recruitment class; credited with building the Bacchus brand; turned around Rami Cosmetics (CEO from 1977); later chaired Dong-A Glass. Master's in business administration; doctorate from Union University (US) per Money Today profile. Order of Civil Merit (Moran Medal); Order of Cultural Merit for art collecting; 27th "Proud Museum Person" award (May 2024). Author of ten books. | About 93 (born c. 1933; inferred from age 71 in Oct 2004 and 88 in Dec 2020) |
Yu Hak-soo (유학수) | President & CEO (Representative Director) | CEO since 1 Jan 2008 (co-CEO with Kim Tae-joon 2008–09); designated successor Dec 2007 | Eldest son of the founder. Declared zero-borrowing management (2012); launched Lavida (2012) and Ample:N (2017). | — |
Yu Seung-hee (유승희) | Director (관장) of Coreana Museum of Art; major shareholder (2.97%) | Co-director of the museum with the founder | Founder's daughter | — |
Other executive officers, CFO and independent directors | — | — | Consult the FY2025 business report, Part VIII (임원 및 직원). | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | Stake (%) | Source / date |
|---|---|---|---|
Treasury shares (Coreana Cosmetics) | ~7,800,000 | 19.50 | Butler (DART-derived), Oct 2026 |
Yu Hak-soo (CEO; reporting representative) | 2,100,000 | 5.25 | Large-shareholding report, 15 Sep 2026 |
Yu Seung-hee (daughter) | 1,187,177 | 2.97 | Same |
Yu Sang-ok (founder) | 1,100,615 | 2.75 | Same |
Coreana Bio (affiliate, 20.20%-owned associate) | 300,000 | 0.75 | Same |
Other related parties (12 persons) | ~1,745,635 | ~4.36 | Derived: group total minus named holders |
Controlling group total (17 persons incl. Yu Hak-soo) | 6,433,427 | 16.08 | Same |
Free float (residual) | ~25,766,573 | ~64.4 | Derived |
Competitive Landscape
Key Competitors
| Competitor | Arena overlap | Scale indicator | Source |
|---|---|---|---|
Amorepacific | Direct sales, prestige skincare, China | Market cap ~KRW 8.6 tn | Simply Wall St (Oct 2026) |
LG H&H | Direct sales, prestige herbal skincare (The Whoo), China | Market cap ~KRW 4.2 tn | Simply Wall St |
APR | Derma / device-led skincare (Medicube), global online | Market cap ~KRW 12.2 tn | Simply Wall St |
Cosmax | ODM incl. China | FY2024 revenue KRW 2,166.1 bn; operating income KRW 175.4 bn; market cap ~KRW 3.4 tn | CNC News (Feb 2025); Simply Wall St |
Kolmar Korea | ODM incl. China (Wuxi) | FY2024 revenue KRW 2,452.1 bn; operating income KRW 195.6 bn; Q2 2026 revenue KRW 861.3 bn, operating income KRW 110.3 bn | CNC News; Cosinkorea (Aug 2026) |
Cosmecca Korea | ODM incl. China (Cosmecca China) | Q3 2025 revenue KRW 182.4 bn; operating income KRW 27.2 bn; FY2024 operating income KRW 60.4 bn; market cap KRW 820.2 bn (May 2026) | Kukinews; Kyobo Securities |
DYD (219550) | Small-cap Korean cosmetics | Market cap ~KRW 47.8 bn | Chickstock (Oct 2026) |
Bonne (226340) | Small-cap Korean cosmetics | Market cap ~KRW 46.6 bn | Chickstock |
J2K Bio (420570) | Small-cap Korean cosmetics | Market cap ~KRW 50.9 bn | Chickstock |
CTK (260930) | Small-cap Korean cosmetics | Market cap ~KRW 43.5 bn | Chickstock |
SD Biotechnologies (217480) | Small-cap Korean cosmetics | Market cap ~KRW 54.8 bn | Chickstock |
Peer Comparison FY2025
| Metric | Coreana (FY2025) | Kolmar Korea (FY2024) | Cosmax (FY2024) | Cosmecca Korea (FY2024) |
|---|---|---|---|---|
Revenue (KRW Bn) | 73.7 | 2,452.1 | 2,166.1 | — |
Revenue growth (%) | -10.6 | 14 | 21.9 | — |
Operating income (KRW Bn) | -4.4 | 195.6 | 175.4 | 60.4 |
Operating margin (%) | -6.0 | 8.0 | 8.1 | — |



